

# Stereoselective nucleophilic substitution of 6-(*tert*-butyldimethylsilyloxy)-3,6-dihydro-2*H*-pyran-3-yl acetate: application to the synthesis of a NK<sub>1</sub> receptor antagonist<sup>☆</sup>

Kazutoshi Sugawara\* and Tomiki Hashiyama

Medicinal Chemistry Research Laboratories, Tanabe Seiyaku Co., Ltd, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan

Received 15 February 2007; revised 15 March 2007; accepted 19 March 2007

Available online 23 March 2007

**Abstract**—Reaction of chiral *cis*- and *trans*-6-(*tert*-butyldimethylsilyloxy)-3,6-dihydro-2*H*-pyran-3-yl acetates with various nucleophiles (allyltrimethylsilane, bistrimethylsilylacetylene, benzyl alcohol, benzyl carbamate etc.) in the presence of a Lewis acid gave the corresponding 2,3-unsaturated pyran derivatives in good to excellent yield with *trans* selectivity. Application to the synthesis of NK<sub>1</sub> antagonist is also described.


© 2007 Elsevier Ltd. All rights reserved.

In our previous paper,<sup>1</sup> we have reported that the reaction of *cis*-(3*S*,6*S*)-6-(*tert*-butyldimethylsilyloxy)-3,6-dihydro-2*H*-pyran-3-yl acetate (**1a**) with allyltrimethylsilane in the presence of a Lewis acid gave a 6-allyl substituted pyran derivative (**2a**) in a highly *trans* selective manner (Scheme 1). In this reaction, the *tert*-butyldimethylsilyloxy group works as a good leaving group. The remarkable stereoselectivity observed in this reaction prompted us to investigate the reactivity and stereoselectivity with various nucleophiles, including C-Nucleophiles, O-Nucleophiles, and N-Nucleophiles, in the presence of a Lewis acid.

As substrates, (3*R*,6*R*)-*cis* (**1b**) and (3*R*,6*S*)-*trans* (**5b**) were employed in order to investigate the influence of the stereochemistry at C-6; they were synthesized from *rac*-**4** in a multi-gram scale through a Lipase-catalyzed

kinetic resolution method, followed by the Mitsunobu reaction (Scheme 2).


Lewis-acid-promoted nucleophilic substitution of **1b** or **5b** with various nucleophiles is summarized in Table 1. The use of catalytic amounts of Sc(OTf)<sub>3</sub> showed comparable yield and selectivity to the stoichiometric use of BF<sub>3</sub>·OEt<sub>2</sub> (entry 1 vs 2). When allylsilane or bistrimethylsilyl acetylene was used as a nucleophile, the Lewis-acid-promoted reaction proceeded with high *trans* selectivity in good to excellent yields irrespective of the stereochemistry of C-6 (entry 1 vs 3, 4 vs 5).<sup>3</sup> The stereochemistry observed in these reactions can be explained by a common oxo-carbenium ion intermediate (Fig. 1). In the intermediate, the acetoxy substituent preferentially adopts a pseudo axial conformation (Aax) over



Scheme 1. Nucleophilic substitution reaction reported.<sup>1</sup>












<sup>☆</sup> Numbering of the products follows pyranone numbering.



\* Corresponding author. Tel.: +81 48 433 2503; fax: +81 48 433 2610; e-mail: k-suga@tanabe.co.jp



Scheme 2. Reagents and conditions: (i) Ac<sub>2</sub>O, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, quant.; (ii) diisopropylazodicarboxylate, PPh<sub>3</sub>, AcOH, THF, rt, 80%.

**Table 1.** Nucleophilic substitution reaction of **1b** or **5b**<sup>a</sup>

Run	Substrates	Nucleophiles	Conditions	Major products <sup>b</sup> (trans:cis)	Yield <sup>c</sup> (%)	Reference
1		 (2.0 equiv)	BF <sub>3</sub> ·OEt <sub>2</sub> (1.3 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -40 °C	 <b>2b</b> (95:5 <sup>&gt;</sup> )	91	1,3
2	<b>1b</b>	 (2.0 equiv)	Sc(OTf) <sub>3</sub> (0.5 mol %) CH <sub>2</sub> Cl <sub>2</sub> , -40 to 0 °C	<b>2b</b> (92:8)	85	3
3		 (2.0 equiv)	BF <sub>3</sub> ·OEt <sub>2</sub> (1.3 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -40 °C	<b>2b</b> (95:5 <sup>&gt;</sup> )	91	1,3
4	<b>1b</b>	TMS—≡—TMS (1.3 equiv)	TiCl <sub>4</sub> (1.3 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -40 °C	 <b>6b</b> (95:5 <sup>&gt;</sup> )	66	3
5	<b>5b</b>	TMS—≡—TMS (1.3 equiv)	TiCl <sub>4</sub> (1.3 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -40 °C	<b>6b</b> (95:5 <sup>&gt;</sup> )	72	3
6 <sup>d</sup>	<b>1b</b>	TMSCN (5.0 equiv)	BF <sub>3</sub> ·OEt <sub>2</sub> (1.5 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -40 to 0 °C or Sc(OTf) <sub>3</sub> (0.5 mol %), CH <sub>2</sub> Cl <sub>2</sub> , rt	 <b>7</b>	Trace	
7	<b>1b</b>	BnOH (1.2 equiv)	BF <sub>3</sub> ·OEt <sub>2</sub> (20 mol %) CH <sub>2</sub> Cl <sub>2</sub> , -40 °C	 <b>8b</b> (82:18)	88	5
8 <sup>e</sup>	<b>1b</b>	BnOCONH <sub>2</sub> (1.0 equiv)	BF <sub>3</sub> ·OEt <sub>2</sub> (1.0 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -40 to 0 °C	 <b>9b</b> (79:21)	71	12
9	<b>1b</b>		Et <sub>3</sub> SiH (2.0 equiv) BF <sub>3</sub> ·OEt <sub>2</sub> (1.2 equiv) CH <sub>2</sub> Cl <sub>2</sub> , -30 to 0 °C	 <b>10</b>	75	12

<sup>a</sup> All reactions were performed in 0.22 M substrate concentration.<sup>b</sup> Product ratio was estimated by using <sup>1</sup>H NMR (300 MHz) analysis of the crude material.<sup>c</sup> Isolated yield.<sup>d</sup> When D-xyral was used as a substrate instead of **1b**, **7** was obtained in 84% yield as shown below.<sup>e</sup> Structures of **9** were elucidated by using NOE analysis shown below.





Figure 1. Oxocarbenium intermediate.

an equatorial one (Aeq) due to the stabilization of the electrostatic interactions between the partially negatively charged oxygen of the substituent and the positively charged carbon of the oxocarbenium ion. Therefore, the nucleophiles can attack the C-6 carbon anti to the acetoxy group.<sup>4</sup>


It is noteworthy that the reaction with TMSCN gave only trace amount of the desired product, in contrast to the same reaction with *D*-xyral (footnote d and entry 6). When benzyl alcohol or benzylcarbamate was used as a nucleophile, the reaction proceeded smoothly in the presence of a catalytic amount of Lewis acid, although with moderate selectivity (entry 7 and 8).

These results suggest that an equilibrium between the *cis*- and *trans*-isomers exists under these conditions.<sup>6</sup> The OTBS group can be easily removed by Et<sub>3</sub>SiH in the presence of BF<sub>3</sub>·OEt<sub>2</sub> (entry 9).

Next, we tried to apply this chemistry to the synthesis of a selective human neurokinin-1 (hNK<sub>1</sub>) receptor antagonist, which has been reported by a group at Merck<sup>7</sup> (Scheme 3). In the synthetic scheme, **12** is a key intermediate in their synthetic array for tetrahydropyran NK<sub>1</sub> antagonists, including **13**.<sup>8</sup> Thus, we chose this compound as a synthetic target. Starting from **1b**, treatment with the known phenethyl alcohol **14**<sup>9</sup> in the presence of a catalytic amount of BF<sub>3</sub>·OEt<sub>2</sub> afforded **15** as an inseparable mixture of epimers (8:1). After hydrolysis of the acetate group, these epimers were readily separated by SiO<sub>2</sub> chromatography to give **16**. The allyl alcohol moiety of **16** was then oxidized with *O*-iodoxybenzoic acid (IBX)<sup>10</sup> to give enone **18**, which was then subjected to phenylcuprate-mediated 1,4-addition in the presence of TMSCl. Crude silyl enol ether was then treated with an aqueous solution of formaldehyde in the presence



Scheme 3. Synthesis of NK<sub>1</sub> antagonists reported by a group at Merck.



Scheme 4. Reagents and conditions: (i) BF<sub>3</sub>·OEt<sub>2</sub> (20 mol %), CH<sub>2</sub>Cl<sub>2</sub>, –30 °C, 93%; (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, **16**: 82%, **17**: 10%; (iii) IBX, DMSO, rt, 91%; (iv) PhMgBr, HMPA, CuBr·SMe<sub>2</sub>, THF, –78 °C, then TMSCl; (v) 37% HCHO, Yb(OTf)<sub>3</sub> (10 mol %), THF, rt; (vi) MS4A, toluene reflux, 72% from **18**; (vii) NH<sub>2</sub>NHTs, TsOH, MeOH, then NaBH<sub>3</sub>(CN), MS4A, THF, 50%.

of Yb(OTf)<sub>3</sub> as a catalyst.<sup>11</sup> Under these conditions, hemiacetal **19** was obtained as an inseparable mixture with the desired **20**. Fortunately, **19** was readily converted to the desired alcohol **20** by simply heating it in toluene in the presence of MS4A. Finally, modified Wolff–Kishner procedure, involving the formation of tosylhydrazone, followed by its reduction with NaBH<sub>3</sub>CN, afforded **12** (Scheme 4). As a result, we synthesized **12** via a seven-step sequence with a 25% overall yield from **1b**.

In conclusion, we investigated the reactivity and stereoselectivity of the nucleophilic substitution reaction of **1b** and **5b** in the presence of a Lewis acid. Furthermore, we showed the utility of this chemistry by the short stereocontrolled synthesis of a NK<sub>1</sub> antagonist. The chemistry developed during the course of this study should allow access to a range of highly substituted tetrahydropyran derivatives, as well as hNK<sub>1</sub> antagonists.

#### References and notes

1. Sugawara, K.; Imanishi, Y.; Hashiyama, T. *Tetrahedron: Asymmetry* **2000**, *11*, 4529.
2. Aggarwal, V. K.; Vennall, G. P. *Tetrahedron Lett.* **1996**, *37*, 3745.
3. Synthesis of **7a** and **7b** from Pentose glycals see: Hosokawa, S.; Kirschbaum, B.; Isobe, M. *Tetrahedron Lett.* **1998**, *39*, 1917, and reference cited therein.
4. Chamberland, S.; Ziller, J. W.; Woerpel, K. A. *J. Am. Chem. Soc.* **2005**, *127*, 5322, and reference cited therein.
5. Synthesis of the enantiomers of **8b** from 3,4-di-*O*-acetyl-D-xylal, see: Cristina, F.; Roberta, G.; Giovanna, M.; Matio, O. T. *Tetrahedron: Asymmetry* **2001**, *12*, 2731, and reference cited therein.
6. When **8b** was treated with BF<sub>3</sub>·OEt<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub> at –40 °C, formation of *cis*-**8b** was detected by HPLC analysis (ca. 15%). In the case of **9b**, *cis*-isomer was detected in CDCl<sub>3</sub> medium after allowing to stand at room temperature for 1 week.
7. Nelson, T. D.; Rosen, J. D.; Smitrovich, J. H.; Payack, J.; Craig, B.; Matty, L.; Huffman, M. A.; McNamara, J. *Org. Lett.* **2005**, *7*, 55, and reference cited therein.
8. Owen, S. N.; Seward, E. M.; Swain, C. J.; Williams, B. J. U.S. Patent 6,458,830 B1, 2001.
9. Brands, K. M. J.; Payack, J. F.; Rosen, J. D.; Nelson, T. D.; Candelario, A.; Huffman, M. A.; Zhao, M.; Li, J.; Craig, B.; Song, Z.; Tschaen, D. M.; Hansen, K.; Devine, P. N.; Pye, P. J.; Rossen, K.; Dormer, P.; Reamer, R. A.; Welch, C. J.; Mathre, D.; Tsou, N. N.; McNamara, J. M.; Reider, P. J. *J. Am. Chem. Soc.* **2003**, *125*, 2129.
10. Frigerio, M.; Santagostino, M. *Tetrahedron Lett.* **1994**, *35*, 8019.
11. Kobayashi, S. *Chem. Lett.* **1991**, *12*, 2187.
12. All new compounds were fully characterized.